Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:54 AM
Ignite Modification Date:
2025-12-25 @ 4:54 AM
NCT ID:
NCT03823118
Eligibility Criteria:
Inclusion Criteria:
* Histological or cytologically confirmed small cell lung cancer;
* Systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence;
* Age 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months
* participants had at least one measurable target lesion by RECIST1.1
* The main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥80 × 109 / L, hemoglobin ≥ 80 g / L;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;
* Patients should participate in the study voluntarily and sign informed consent
Exclusion Criteria:
* Patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al.
* Subjects with symptomatic brain metastases;
* Patients whose primary lesion with active bleeding within 4 months
* Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg
* Patients with active or unable to control serious infections
* Patients who are pregnant or breastfeeding.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT03823118
Study Brief:
Protocol Section:
NCT03823118